


Article

Negative Regulation of BOK Expression by Recruitment of TRIM28 to Regulatory Elements in Its 3' Untranslated Region



Yuniel Fernandez-Marrero, Daniel Bachmann, Emanuel Lauber, Thomas Kaufmann

thomas.kaufmann@pki.unibe.ch

HIGHLIGHTS

BOK mRNA is destabilized by AU-(mouse) or U-rich (human) elements within its 3' UTR

Mutation of these ARE/URE sequences results in increased BOK RNA and protein levels

TRIM28 represses BOK expression by associating with the UREs of human BOK mRNA

Inverse correlation of TRIM28 and BOK levels predicts survival in selected cancers

Fernandez-Marrero et al.,
iScience 9, 461–474
November 30, 2018 © 2018
The Author(s).
<https://doi.org/10.1016/j.isci.2018.11.005>

Article

Negative Regulation of BOK Expression by Recruitment of TRIM28 to Regulatory Elements in Its 3' Untranslated Region

Yuniel Fernandez-Marrero,¹ Daniel Bachmann,¹ Emanuel Lauber,^{1,2} and Thomas Kaufmann^{1,3,*}**SUMMARY**

BCL-2-related ovarian killer (BOK) is a pro-apoptotic BAX-like member of the BCL-2 family with suggested tumor suppressor activity. The molecular mechanisms regulating BOK expression are poorly understood and fail to explain a frequent lack of concordance between protein and transcript levels. Here, we describe a potent post-transcriptional mechanism that negatively regulates BOK expression mediated by conserved (AU/U)-rich elements within its 3' UTR. Using proteomics approaches we identified TRIM28 as a key component associating with U-rich elements in the human BOK 3' UTR, resulting in a dramatic reduction of BOK expression. TRIM28 is overexpressed in several cancers, correlating with poor patient outcome, whereas the BOK locus is frequently deleted or its expression downregulated in human cancers. Data mining indicated that, for certain cancers, high TRIM28 and low BOK expression are significantly correlated in the stratum of patients with the worst survival, suggesting that this mechanism might be of potential therapeutic value.

INTRODUCTION

The abundance of a protein results from the interplay of epigenetic, (post-)transcriptional, and (post-)translational events. The post-transcriptional control of gene expression is based on the recruitment of RNA-binding proteins (RBP) (Glisovic et al., 2008) to homing sequences on the target messenger RNA (mRNA) via RNA-recognition motifs (Lunde et al., 2007). Prominent mechanisms in that respect include micro RNA (miRNA) (Biggar and Storey, 2015) and AU-, U- or GU-rich elements mediating RNA decay (Vlasova-St Louis and Bohjanen, 2014).

Contrary to miRNA-based regulation, AU-rich element (ARE)-based mechanisms do not require annealing of complementary RNA strands but a direct recruitment of RBP to the target transcript. These elements are preferentially localized in the 3' untranslated region (3' UTR) of the mRNA. Initially, this mechanism was described only for the pentamer AUUUU, whereas later experimental evidence revealed that extended variants reaching up to 13-mers, as well as GU- and U-rich sequence patterns, were likewise able to modulate the half-life of transcripts (Fallmann et al., 2016). Moreover, the impact of these elements on mRNA stability is determined by the nature of the recruited RBP, which can be grouped into mRNA stabilizers, such as *ELAVL1* (Wigington et al., 2015), *NCL* (Sengupta et al., 2004), and *ZMAT3* (Vilborg et al., 2009), or mRNA destabilizing members, such as *HNRNPD* (Ishimaru et al., 2010) and *ZFP36* (Murata et al., 2005).

Although ARE-mediated mRNA modulation is known to influence the landscape of gene expression (Bakheet et al., 2018), its impact on members of the BCL-2 family, which are key regulators of the intrinsic (mitochondrial) apoptotic pathway, is poorly understood, with the notable exception of BCL-2 itself. The expression of BCL-2 has been shown to be influenced by the balance of *HNRNPD* and *NCL* recruited to the 3' UTR of its transcript, with implications for the integrity of the mouse B cell compartment upon deletion of critical AREs therein (Diaz-Munoz et al., 2015; Schiavone et al., 2000).

BCL-2-related ovarian killer (BOK) is a member of the BCL-2 family closely related to the pro-apoptotic multi-BH-domain containing members BAX and BAK (Fernandez-Marrero et al., 2017; Ke et al., 2018; Zheng et al., 2018). Although BOK has a particularly high affinity for the ER and associated membranes, its enforced accumulation or overexpression leads to intrinsic apoptosis, suggesting that cellular BOK levels need to be tightly regulated in healthy cells (Echeverry et al., 2013; Llambi et al., 2016; Rabachini et al., 2017). Interestingly, there are indications of selective loss of BOK in cancer, as the genomic locus

¹Institute of Pharmacology, Faculty of Medicine, University of Bern, Inselspital, INO-F, 3010 Bern, Switzerland

²Present address: Anatomy Unit, Section of Medicine, University of Fribourg, Route Albert-Gockel 1, 1700 Fribourg, Switzerland

³Lead Contact

*Correspondence: thomas.kaufmann@pki.unibe.ch

<https://doi.org/10.1016/j.isci.2018.11.005>



containing the human *BOK* gene is deleted in a substantial percentage (average 15%) of human cancers (Beroukhi et al., 2010). We recently showed that *BOK* is downregulated in patients with late stage (lymph node positive) versus early stage non-small cell lung cancer (NSCLC), with high *BOK* protein levels being predictive of extended patient survival (Moravcikova et al., 2017). Likewise, *BOK* was shown to be downregulated and of prognostic value in colorectal carcinoma (Carberry et al., 2018). Current understanding of the mechanism(s) regulating these changes in *BOK* abundance is meagre, restricted to epigenetic regulation by promoter methylation (Moravcikova et al., 2017) or selective proteasomal turnover, which seems to be linked to the localization of *BOK* at the ER and regulated by the ERAD pathway and the interaction of *BOK* with inositol triphosphate receptors (Llambi et al., 2016; Schulman et al., 2013, 2016).

Tripartite Motif Containing 28 (TRIM28/TIF1- β /KAP1) is a co-repressor multidomain protein acting together with Krüppel-Associated Box Zinc Finger Protein (KRAB-ZNF) transcription factors (Friedman et al., 1996; Moosmann et al., 1996), nucleosome remodeling deacetylase (NuRD), and heterochromatin-associated protein 1 (HP1) (Cheng et al., 2014) to silence multiple genes at the chromatin level. These interactions sustain the role of TRIM28 as a regulatory hub in multiple processes such as the maintenance of cell stemness (Hu et al., 2009), inhibition of p53 activity (Okamoto et al., 2006), transcriptional repression (Groner et al., 2010), and epithelial-mesenchymal transition (EMT) (Venkov et al., 2007). Interestingly, despite its key role in regulating chromatin activity (Alexander et al., 2015) and direct gene transcription (Bunch et al., 2014), TRIM28 lacks obvious DNA-binding domains and thus depends on adaptor proteins to localize to the DNA (Iyengar and Farnham, 2011). The functional pleiotropism of TRIM28 has been linked to tumorigenesis, and studies with human cancer cell lines or xenografts highlight the contribution of TRIM28 to sustained mTOR activation and cell cycle progression (Li et al., 2018), sustained Warburg effect (Jin et al., 2017), and maintenance of the cancer stem cell niche (Czerwinska et al., 2017). Moreover, from a clinical perspective, TRIM28 has been reported to be overexpressed in cervical (Li et al., 2018), hepatocellular (Jin et al., 2017), breast (Czerwinska et al., 2017), and ovarian (Cui et al., 2014) cancers, in all of which it is associated with a poor clinical prognosis.

Here, we describe a regulatory circuit controlling *BOK* expression at the transcript level, involving conserved (AU/U)-rich elements (ARE/URE) present in the 3' UTRs of both human and mouse *BOK* mRNA. Remarkably, negative regulation of human *BOK* expression through mRNA destabilization depends on the unexpected association of TRIM28 with these URE sites. Furthermore, TRIM28-dependent repression specifically targets *BOK*, whereas it does not affect the pro-apoptotic multidomain BCL-2 family members BAX and BAK. This TRIM28-mediated negative regulation of *BOK* might have important clinical implications since *TRIM28*^{high}*BOK*^{low} levels were associated with poor patient survival in certain cancer (sub-)types.

RESULTS

The 3' Untranslated Region of Mouse *Bok* mRNA Contains a Strong Negative-Regulating AU-Rich Element

We noticed that the architecture of the mouse *Bok* mRNA dramatically influences protein expression levels upon transient transfection into the human embryonic kidney cell line HEK293T, which expresses barely detectable levels of endogenous *BOK*. To further study this phenomenon, we generated a series of expression constructs consisting of the *Bok* coding sequence (CDS) harboring permutations of the 5' and 3' UTR or truncated versions of the latter (Figure 1A). Although transfection of *Bok* CDS (or FLAG-tagged *Bok* CDS) resulted in strong protein expression, it was barely detectable when *Bok* cDNA was used (Figure 1B). This was an indication for the presence of one or more negative regulatory elements in either the 5' and/or the 3' UTR of *Bok* mRNA. As depicted in Figure 1C, the expression of *Bok* CDS containing either the 3' UTR or the 5' UTR demonstrated that it is the 3' UTR that is responsible for the observed repression.

To map the position of the regulatory sequence(s) present in the 3' UTR, we generated three deletion mutants of the mouse *Bok* CDS-3'UTR construct, in which similarly sized parts within the 3' UTR were removed (3' UTR Δ 1, 183 bp; 3' UTR Δ 2, 207 bp; and 3' UTR Δ 3, 234 bp) (Figure 1A). Co-transfection of these mutants (together with pcDNA3/EGFP at a ratio of 1:10 for normalization of transfection efficiencies) into HEK293T cells and subsequent analyses by qPCR and western blotting demonstrated that region 1 (most proximal to the stop codon) contained all of the negative regulatory element(s) (Figure 1D). Furthermore, the concordance observed in Figure 1D (right panel) between transcript and protein levels indicated that the negative regulatory element likely affects *Bok* mRNA stability, resulting in its degradation.




Figure 1. Identification of a Negative Regulatory Element in the 3' UTR of Mouse *Bok*

(A–E) (A) List of constructs generated to narrow down the region containing destabilizing elements in the mouse *Bok* transcript sequence. Western blot analysis of BOK levels in total protein extracts prepared from HEK293T cells transiently transfected with (B) *Bok* cDNA or *Bok* CDS (with or without N-terminal FLAG tag), (C) *Bok* CDS with or without its 5' UTR and/or 3' UTR, (D) *Bok* CDS combined with the full length or truncated version of its 3' UTR, or (E) *Bok* CDS combined with its wild-type 3' UTR or harboring discrete point mutations in a predicted AU-rich element (ARE) therein. Each immunoblot is representative of at least three independent experiments. Tubulin and/or EGFP were used to normalize the transfection efficiency and gel loading. The double band detected for BOK corresponds to the full-length protein and a shorter version translated from a cryptic start codon at methionine 15 (Schulman et al., 2016). Bar graphs to the right of panels D and E show the quantification of BOK levels from quantitative immunoblots (using near-infrared fluorochromes) and real-time quantitative PCR. The data are presented as mean ± SD, N = 3. Statistical analysis was performed using a one-way ANOVA followed by a Tukey post-hoc test in GraphPad Prism. Significance levels, p > 0.05^{ns}, p < 0.01^{**}, p < 0.001^{***}.




Figure 2. Validation of Mouse BOK 3' UTR Regulatory Function in Autologous Cells and an Unrelated Coding Sequence

(A) The functionality of the ARE-mediated regulation mechanism in autologous cells was evaluated at the protein and mRNA levels by transiently transfecting mouse *Bok* CDS, CDS-3'UTR, and CDS-3'UTR(AREmut) expression constructs into *Bok*^{-/-} SV40 MEF. Transfection efficiency was normalized to a co-transfected pcDNA3/EGFP vector.

(B and C) (B) Expression of chimeric EGFP constructs flanked by mouse *Bok*'s 5' and 3'-UTR, with or without ARE-specific mutation, transiently transfected into HEK293T cells or (C) *Bok*^{-/-} SV40 MEF. The transfection efficiency was normalized to a co-transfected pcDNA3/FLAG-MCL-1 vector. The data of quantitative immunoblotting are presented as mean \pm SD, N = 3.

Statistical analysis was performed using a one-way ANOVA followed by a Tukey *post-hoc* test in GraphPad Prism. Significance levels, $p < 0.0001$ ****.

We next made use of the AREsite2 prediction tool (<http://nibiru.tbi.univie.ac.at/AREsite2/>) (Fallmann et al., 2016) to identify regulatory elements in the mouse *Bok* 3' UTR and found one sequence corresponding to an ARE located within the 3' UTR region 1 (position 1,049–1,053, sequence AUUUA) (Figure 1A). As shown in Figure 1E, site-directed mutagenesis of this ARE site (AUUUA \rightarrow GACGU) restored both *Bok* mRNA and protein expression to levels comparable with expression of the CDS alone. Taken together, these data demonstrate that a single ARE site within the proximal region of the 3' UTR strongly compromises mouse *Bok* mRNA stability, resulting in decreased protein expression.

The Mouse *Bok* ARE Sequence Suppresses the Expression of Unrelated Coding Sequences

Considering that the initial experiments were performed with mouse *Bok* expression constructs in a human cell line we next wanted to confirm our findings in an autologous cell model, namely, SV40 immortalized *Bok*^{-/-} mouse embryonic fibroblasts (MEF) (Echeverry et al., 2013). Similar to HEK293T cells, transfection of the mouse *Bok* CDS into *Bok*^{-/-} MEFs resulted in a strong protein signal by western blotting, whereas it was barely detectable when the entire cDNA was transfected (Figure 2A). Mutation of the ARE site restored BOK protein levels to approximately 70% of the positive control, demonstrating that the

ARE-mediated regulatory mechanism is functional in both human and mouse cells (Figure 2A). qPCR analysis confirmed that BOK protein levels correlated with mRNA levels (Figure 2A).

The previous results supported the existence of a conserved regulation of *Bok* expression through its 3' UTR. We next tested whether the 3' UTR could also modulate unrelated coding sequences. To this purpose, we evaluated the expression of enhanced green fluorescent protein (EGFP) flanked by the 5' and 3' UTRs of mouse *Bok*, with or without mutation of the ARE site. In line with our previous results, the inclusion of the *Bok* 3' UTR massively reduced EGFP expression in both HEK293T and *Bok*^{-/-} SV40 MEF, whereas the ARE mutation led to a significant rescue of EGFP levels (Figures 2B and 2C). These data indicate that the ARE sequence in the mouse *Bok* 3' UTR is a genuine repressor of gene expression irrespective of the upstream coding sequence.

The Human BOK 3' UTR Contains U-Rich Regulatory Elements

Despite similar exon-intron organization of the mouse and human BOK genes, a remarkable difference resides in the lengths of their respective 3' UTRs, with the human 3' UTR being three times longer than its mouse counterpart; nevertheless, human BOK expression was also found to be strongly repressed by its 3' UTR (Figure 3A). Using *in silico* tools described earlier, we screened for the existence of ARE sites in the human BOK 3' UTR, also including related GU/CU- and U-rich elements in the analysis. Contrary to the mouse transcript, the human 3' UTR lacks classical ARE sites (core sequence AUUUA) but contains six stretches of non-canonical U-rich elements (five URE, motifs W¹⁻²UUUW¹⁻², and one AWTA AAA motif, W=U/A) (Figure S1). These six sequences overlapped to some degree and could be reduced to three potential U-rich elements we termed URE1, 2 and 3, respectively (Figure 3B). Site-directed mutagenesis of these sites showed that individual destruction of either URE1 or 2 partially recovered BOK mRNA and protein expression, whereas mutation of URE3 did not show any effect (Figure 3C). However, simultaneous mutation of URE1 and 2, or of all three URE sites (URE1-3), significantly recovered BOK expression to levels approaching those seen for the transfection control with the CDS (Figure 3C). These results indicate that the 3' UTR-dependent negative regulation of BOK is conserved between mice and humans. Furthermore, similar to the single destabilizing ARE site in the mouse *Bok* transcript, there are two U-rich elements (URE1 and 2) present in the human BOK 3' UTR exerting a comparable regulatory role.

Identification of URE-Binding Proteins in the 3' UTR of Human BOK by Proteomics Approaches

To identify proteins binding to the URE elements within the human BOK 3' UTR and being critical for its repression, we performed a protein pull-down from HEK293T-derived cell lysate using synthetic biotinylated RNA probes encoding human BOK CDS bearing the wild-type or the URE mutated (UREmut1-3) version of the 3' UTR, followed by identification by mass spectrometry. Initial analysis using silver staining on SDS-PAGE-separated samples already indicated differences in the protein binding to each probe compared with the beads-only negative control (Figure 4A). Overall, 749 hits were identified, of which 246 (33%) were unique to at least one of the three studied samples (Figure 4B and Table S1). A total of 101 hits were overrepresented more than 1.5 times in the samples pulled down with the wild-type probe compared with the UREmut1-3 probe (Figure 4B). Additional filtering criteria using adjusted p values and false discovery rate led to a final list of 84 candidates that were clustered in three major categories according to the differential abundance among the probes and the background (Figure 4C). Of particular interest were the resulting hits in clusters 1 and 3, as they displayed the most dramatic differences between wild-type and UREmut1-3 probes; thus, candidates from these clusters were selected for the validation round. Furthermore, we performed an overrepresentation gene ontology test with the selected 106 candidates (Figure 4D) and found a significant enrichment in proteins involved in biological processes related to RNA metabolism, processing, and splicing. This group contained several proteins known to assemble into (macro)molecular complexes, which, surprisingly, are not only restricted to the above-mentioned splicing and mRNA 3'-end processing pathways, but also involved in DNA fragmentation during apoptosis, according to the annotation of the Reactome Pathway database (Fabregat et al., 2018).

TRIM28 Negatively Regulates Human BOK Expression through Association with 3' UTR Contained U-Rich Elements

To validate URE-binding candidates for their role in destabilizing BOK mRNA in living cells, we performed transfections of pooled endoribonuclease-prepared short interfering RNAs (esiRNA) in HEK293T cells stably expressing either the human BOK CDS-3'UTR or its URE mutated version (UREmut1-3). We evaluated




Figure 3. Discovery of Analogous Negative Regulatory Elements in the 3' UTR of Human BOK Transcript

(A) Transient transfection into HEK293T cells of human BOK CDS or its coding sequence fused to its 3' UTR, highlighting the occurrence of negative regulators in the 3' UTR.

(B) List of constructs generated used to validate the functionality of the predicted U-rich destabilizing elements (URE) within the human BOK transcript sequence (see also Figure S1).

(C) Representative immunoblot showing BOK levels in HEK293T cells transiently transfected with the indicated human BOK expression constructs. The right panel shows the levels of BOK obtained from quantitative immunoblotting using near-infrared fluorochromes and real-time quantitative PCR quantification from three independent experiments. The data are presented as mean \pm SD, N = 3.

Statistical analysis was performed using a one-way ANOVA followed by a Tukey post-hoc test in GraphPad Prism. Significance levels, $p > 0.05$ ^{ns}, $p < 0.05$ ^{*}, $p < 0.01$ ^{**}, $p < 0.001$ ^{***}.

several candidates belonging to the clusters defined in Figure 4C (*TRIM28*, *LSM5*, *SAFB2*) as well as one hit (*TIAL1*) that fell below the selection threshold (p value ≤ 0.05 , fold change 3' UTR/3' UTR UREmut1-3 ≥ 1.5) but is a known regulator of mRNA stability, which served as a negative control (Wigington et al., 2015; Zhao et al., 2014).

From this validation round, only knockdown of *TRIM28* produced a robust and statistically significant recovery of BOK protein levels in cells expressing exogenous BOK fused to the wild-type 3' UTR but not the URE1-3 mutated version (Figure 5A). *TRIM28*, also known as KAP1/TIF1- β , is a known co-repressor of gene expression at the chromatin level (Hosoya et al., 2013). To strengthen our finding of *TRIM28* acting at the mRNA level rather than at the genomic BOK locus, we transiently co-transfected *TRIM28*-specific esiRNA with *BOK-3'UTR* or *BOK-3'UTR(UREmut1-3)* expression plasmids into HEK293T cells and confirmed that the knockdown of *TRIM28* only rescued BOK expression in those cells receiving the *BOK-3'UTR* construct, up to 70% compared with the control *BOK-3'UTR(UREmut1-3)* (Figure 5B). Furthermore, we corroborated the presence of endogenous *TRIM28* protein in pull-down fractions from lysates prepared from the human cell lines HEK293T, HCT-116, and NCI-H1299 using biotinylated *CDS-3'UTR* RNA probe. However, the signal was reduced to non-specific binding (comparable with beads-only control) when using




Figure 4. Identification of Proteins Binding to the UREs within the Human BOK 3' UTR

(A and B) HEK293T lysates were incubated with biotinylated RNA probes encoding human *BOK* CDS-3'UTR or CDS-3'UTR(UREmut1-3), a version with the three predicted URE sites mutated. Pull-down fractions were analyzed for the presence of RNA-binding proteins by SDS-PAGE and silver staining (A) and shotgun tandem mass spectrometry (MS/MS). The proteins detected were represented with a Venn diagram reflecting the count of detected proteins per sample type (B upper panel) and a volcano plot with the ratio and statistical significances shown between the indicated probes (B lower panel). Vertical (magenta) and horizontal (green) dashed lines mark the thresholds for absolute fold change ($\geq \pm 1.5$) and p values ($p \leq 0.05$). A continuous color scale is applied to each point in accordance to the estimated false discovery rate (FDR < 1%). Values corresponded to averages from three independent experiments.

(C) Clustering of the paired sample ratio abundances for the identified hits.

Figure 4. Continued

(D) A total of 106 candidates with a positive fold change (≥ 1.5) were analyzed in the database Panther (<http://pantherdb.org/>) for overrepresentation within four gene ontology categories performing a Fischer test with FDR correction. Bars represent the $-\log_{10}$ -transformed corrected p value and are filled according to the calculated fold enrichment against the corresponding human genome background.

the *CDS-3'UTR(UREmut1-3)* probe, strengthening the evidence that TRIM28 indeed binds to the UREs present in the 3' UTR of BOK (see [Figures 5C](#) and [S2](#) for predicted RNA-binding motifs in TRIM28).

This functional link between BOK repression and TRIM28 could further be demonstrated by performing the opposite approach, in which we transiently overexpressed TRIM28 in the BOK-proficient colorectal cancer cell line HCT-116 or the NSCLC cell line NCI-H1299. As shown in [Figure 5D](#), overexpression of HA-tagged TRIM28 resulted in a significant reduction of >50% of endogenous BOK protein levels compared with the control vector. This modulation of endogenous BOK expression was independently confirmed in NCI-H1299 and LXF-289 lung cancer cell lines stably transduced with HA-TRIM28 ([Figures 5E](#), [S3B](#), and [S3C](#)). Of note, this functional association with TRIM28 was specific for BOK within the pro-apoptotic multi-domain family members, since the expression levels of BAX and BAK remained unchanged under the same experimental conditions ([Figure 5D](#)). Given the high level of homology between human and mouse TRIM28, we transfected human TRIM28 into MEF and likewise found reduction in endogenous (mouse) BOK protein levels, supporting a similar mode of action of TRIM28-mediated BOK repression in mouse cells ([Figure S3A](#)). Taken together, these data demonstrate that TRIM28 recruitment to URE sites in the 3' UTR of human BOK mRNA results in a potent repression of BOK cellular abundance.

BOK and TRIM28 are Negatively Correlated in Selected Types of Cancer

Our previous results demonstrated a negative impact of TRIM28 levels on BOK expression. We next sought to address whether this phenomenon could be detected in the publicly available Cancer Genome Atlas (TCGA) database. As previously reported, we found that elevated transcript levels of *TRIM28* constitute a risk factor in several cancer types, whereas *BOK* transcript levels mostly show an opposite trend (i.e., decreased in cancer), with the notable exception of adrenocortical cancer and skin cutaneous melanoma ([Figures S4](#) and [S5](#)). Simultaneous modeling of *BOK* and *TRIM28* levels using multiparametric Cox hazard ratio models in primary tumors derived from patients with kidney clear cell or papillary cell carcinoma as well as hepatocellular carcinoma indicated a significant reduction in the risk of death for patients with elevated *BOK* levels, which contrasts with the increased risk of death associated with high *TRIM28* expression ([Figure 6A](#)). Supporting these models, patients who simultaneously had *BOK* levels above and *TRIM28* levels below their respective population medians exhibited the best survival rate, in stark contrast to those patients belonging to the opposite strata ([Figure 6B](#) see [Table S2](#)). Interestingly, in kidney malignancies, *TRIM28* and *BOK* expressions are negatively correlated in the patient stratum with the highest mortality rate, whereas it is less clear for liver and lung carcinomas ([Figure 6C](#) see [Table S2](#)). Overall, these data strengthen the interrelationship between *TRIM28* and *BOK* expression indicating that, in these selected cancers, the negative correlation between *TRIM28* and *BOK* may potentially be of prognostic clinical value.

DISCUSSION

BOK is emerging as a BCL-2 family member of increasing interest, both during development as well as in its role as a potential tumor suppressor or modulator of cancer behavior ([Carberry et al., 2018](#); [Ke et al., 2018](#); [Moravcikova et al., 2017](#); [Rabachini et al., 2017](#)). Owing to the pro-apoptotic response resulting from its accumulation, *BOK* expression seems to be tightly regulated at various levels. Here we expand this complexity by describing the existence of AU- and U-rich elements (ARE/URE) within the 3' UTR of mouse or human *BOK* mRNAs, respectively, both of which contribute to the negative regulation of BOK expression.

Our model provides an alternative yet non-excluding explanation to the previously described epigenetic and proteasomal regulation of BOK levels ([Llambi et al., 2016](#); [Moravcikova et al., 2017](#)). The existence of (A/U)RE could uncouple the transcription rate of the *BOK* genomic locus from its total protein concentration, explaining previously observed inconsistent correlations between BOK protein and mRNA levels in some mouse tissues and NSCLC biopsies ([Echeverry et al., 2013](#); [Moravcikova et al., 2017](#)).




Figure 5. Validation of Selected BOK Negative Regulator Candidates

(A) HEK293T cells stably expressing human BOK constructs CDS-3'UTR or CDS-3'UTR(UREmut1-3) were transfected with validated esiRNAs targeting the candidates *LSM5*, *TRIM28*, *SAFB2*, and *TIAL1*. The recovery of BOK protein levels was used to determine involvement of a candidate in the URE-mediated repression of BOK. Immunoblots shown are representative of three independent experiments, and the quantification (right panel) of the signal is presented as mean \pm SD. Statistical differences were determined using a one-way ANOVA followed by a Tukey post-hoc test.

(B) BOK recovery in HEK293T cells transiently co-transfected with human *BOK* CDS-3'UTR and esiRNA targeting *TRIM28*. The 3'UTR(UREmut1-3) construct was used as a 100% reference.

(C) Demonstration of the specific recruitment of endogenous *TRIM28* to the 3' UTR of human *BOK* in three independent cell lines using the indicated biotinylated synthetic probes (see Figure S2 for prediction of RNA binding motifs in *TRIM28*).

(D) Transient overexpression of HA-tagged *TRIM28* in the lung cancer cell line NCI-H1299 or the colon carcinoma cell line HCT-116 leads to downregulation of endogenous BOK without impacting on the levels of BAX or BAK. Quantitative immunoblots are representative of three independent experiments; data are presented as mean \pm SD. Statistical

Figure 5. Continued

differences were detected using an unpaired t test, comparing with the BOK levels obtained on the sample transfected with the empty vector. Downregulation of BOK by overexpressed HA-TRIM28 correlates with reduced BOK mRNA levels (means \pm SD, N = 3).

(E) Stable expression of HA-tagged TRIM28 in the lung cancer cell lines NCI-H1299 and LFX-289 leads to a reduction of endogenous BOK levels. See [Figure S3B](#) for quantification.

Significance levels, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$.

In our experimental setting, the (A/U)RE elements in the mouse and human BOK 3' UTRs exclusively acted as a negative regulators, which even worked for unrelated coding sequences, contrasting with the dual role of ARE sequences in both stabilization and destabilization of the mRNA of other genes, such as *BCL-2* ([Diaz-Munoz et al., 2015](#); [Schiavone et al., 2000](#)). This dominance of the BOK 3' UTR to suppress its transcript abundance and protein expression also suggests that the post-transcriptional control of BOK may dominate over its translational regulation, e.g. ribosome scanning or cap-(in)dependent translation, which is traditionally exerted by the 5' UTR region ([Leppek et al., 2018](#)).

In human cells, we showed that 3' UTR-dependent repression of *BOK* involves the recruitment of TRIM28 to the URE elements. This is a striking observation since all known repressing activities of TRIM28 occur at the chromatin level ([Bunch et al., 2014](#); [Li et al., 2017](#)), and more importantly, TRIM28 lacks classical nucleic-acid-binding motifs ([Iyengar and Farnham, 2011](#)). Considering this, TRIM28 is likely recruited as part of a multiprotein complex to the 3' UTR-URE sites rather than directly binding to the RNA. However, the latter possibility warrants further investigation since analysis of TRIM28 amino acid sequence with the Web tool catRAPIDsignature ([Livi et al., 2016](#)) predicts multiple modules with potential RNA-binding activity ([Figure S2](#)). Furthermore, experimental evidence from the Landthaler group, characterizing the transcript-bound proteome in HEK293T cells, detected TRIM28 in two of three mass spectrometry runs ([Baltz et al., 2012](#)), supporting the possibility of true mRNA binding of TRIM28. Regarding the underlying mechanism of mRNA degradation, it will be interesting to investigate whether TRIM28 requires its SUMO E3 ligase activity or not. Involvement of E3 ligase activity in such a context has been described for other RNA-binding E3 ligases, such as MEX-3C, which mediates a RING-dependent destabilization of MHC-I transcripts ([Cano et al., 2012](#)).

The repression of BOK in human cells was TRIM28 dependent as demonstrated both by RNA interference and overexpression of TRIM28 in several independent cell lines. This mechanism seems peculiar for *BOK*, since our mass spectrometry data showed absence of *ELAVL1* and tristetraprolin (*TTP*), two of the most common mediators of ARE-based RNA decay in the human transcriptome ([Bakheet et al., 2018](#)). Another feature of TRIM28-mediated regulation seems to be the specificity for *BOK* over its pro-apoptotic multidomain relatives *BAX* and *BAK*. This might result from the type, abundance, and position of the predicted URE sites in the respective 3' UTRs of these particular genes, which at the same time greatly diverges from the best studied ARE-regulated protein of the whole family, the *BCL-2* gene ([Figure S1](#)).

Our proteomic approach combined with independent protein pull-downs using biotinylated RNA probes undoubtedly placed TRIM28 at the mRNA level; separating its known role at the chromatin from our discovered function at the mRNA level was challenging. Therefore, we performed our assays using transient transfections and collecting the samples within a short temporal window, as well as included some assays using stable transfections. These assays indicated that relatively high levels of TRIM28 may be required to repress *BOK* mRNA. It is further possible that TRIM28 may affect BOK protein stability directly (e.g., in LFX-289 cells), and further investigation in that direction is needed. The transient approach allowed us to minimize the likelihood of chromosomal integration of the transfected BOK expression constructs, increasing the chance of a transcript-based regulatory mechanism.

Our results provide a potential value of the TRIM28-dependent, URE-mediated decay of *BOK* mRNA in certain cancers, particularly in subtypes of kidney and lung carcinomas, considering their inverse correlation in the stratum of patients with the worst overall survival and/or risk of event. It should be noted, however, that, as a limitation of these results, such an inverse correlation was only shown at the mRNA level but not yet interrogated at the protein level. *TRIM28* is increased in several cancerous malignancies, and increased TRIM28 is a poor prognosis factor in early-stage NSCLC ([Liu et al., 2013](#)), glioma ([Qi et al., 2016](#)), and colorectal cancer ([Fitzgerald et al., 2013](#)). Furthermore, TRIM28 increases the expression of the ATP-binding cassette genes *ABCG2* and *ABCB1*, thus contributing to chemoresistance to paclitaxel




Figure 6. Potential Clinical Implications of the TRIM28 and BOK Interrelationship

(A–C) (A) Multiparametric Cox hazard ratio modeling of *BOK* and *TRIM28* mRNA levels in several cancer types. Number of patients (N), 95% confidence interval of the hazard ratio function (HR 95% CI), significance (p value), and overall significance of the model (Model p value) are tabulated. Patients were classified according to their *BOK* and *TRIM28* levels with respect to each gene population median expression into two strata (“high”/“low”) and further analyzed for overall survival (B) and correlation of the two genes within each strata (C). Differences in survival were detected with the log rank test, and correlations were determined using the Spearman’s estimate. Significance levels, $p > 0.05$ ^{ns}, $p < 0.05$ ^{*}, $p < 0.01$ ^{**}, $p < 0.001$ ^{***}. See Table S2 for original and full data.

and cisplatin of epithelial ovarian cancer cells (Hu et al., 2015). On the contrary, pro-apoptotic *BOK* is currently discussed as a potential tumor suppressor gene, since its genomic locus is deleted across various cancers (Beroukhim et al., 2010) and elevated levels of this protein are associated with enhanced overall survival of patients with lymph-node-positive lung cancer (Moravcikova et al., 2017). It is currently not clear whether *TRIM28*-mediated repression of *BOK* levels primarily affects apoptotic responses or whether recently described “non-apoptotic” roles of *BOK* need to be considered as well (D’Orsi et al., 2016; Kalkat et al., 2013; Moravcikova et al., 2017; Rabachini et al., 2017). Along that line, a molecular process potentially linking *TRIM28* and *BOK* could be EMT. Knockdown of *TRIM28* was shown to impair EMT in ovarian cancer cells by upregulation of E-cadherin (*CHD1*) and reduction of vimentin (*VIM*) and N-cadherin (*CDH2*) (Deng et al., 2017). Along the same line, Chen and colleagues reported that, in NSCLCs, TGF β -induced EMT is dependent on induction of *TRIM28*, strongly suggesting that *TRIM28* contributes to EMT in NSCLC (Chen et al., 2014). *TRIM28* was further shown to promote EMT and metastasis in breast cancer (Wei et al., 2016). Strikingly these phenotypes reported for downregulation or overexpression of *TRIM28* with regards to EMT are inversely mimicked by *BOK*, as we have recently shown for NSCLC cells that overexpression of *BOK* antagonizes TGF β -induced EMT (Moravcikova et al., 2017), thereby further underlining the connection and opposing functions of *TRIM28* and *BOK* in a cancer context.

In summary, we have identified a post-transcriptional negative regulation of *BOK* expression through association of *TRIM28* with distinct URE present in the 3’ UTR of the *BOK* transcript, resulting in destabilization and decay of the latter. This mechanism seems to rather specifically affect *BOK*, while sparing other pro-apoptotic multi-domain BCL-2 family members. Future efforts should focus on integrating this regulatory mechanism into the various (patho)physiological functions that have been described for *BOK*, in particular corroborating its relevance to cancer biology and its potential use by cancer cells to evade current chemotherapeutic regimens and/or to promote malignant transformation, including metastasis.

Limitations of the Study

Recent advances in elucidating the role of BOK in health and disease suggest that its abundance could be a critical factor to the cellular fate. Nevertheless, we lack comprehensive understanding of how BOK levels are regulated. Our work provides another layer of BOK regulation, involving the description of destabilizing (AU/U)-rich elements in the 3' UTR of its mRNA. We currently do not know if and how strongly these regulatory elements contribute to physiology in development or in adult life. One of the destabilizing factors identified to associate with the U-rich elements of human BOK 3' UTR is TRIM28. It is not clear whether TRIM28 directly binds to mRNA or indirectly as part of a macromolecular protein complex and through which mechanism TRIM28 induces mRNA destabilization.

METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Transparent Methods, five figures, and two tables, and can be found with this article online at <https://doi.org/10.1016/j.isci.2018.11.005>.

ACKNOWLEDGMENTS

We thank Drs. X. Wang and P. Jost (Munich, Germany) for scientific discussion and the Proteomics and Mass Spectrometry Core Facility at the Department for BioMedical Research (DBMR), University of Bern, for running the mass spectrometry, interpreting the data, and evaluating the primary results. This work was supported by the Swiss National Science Foundation (project grant 31003A_173006, to T.K.). Y.F.-M. was a PhD student of the Graduate School of Cellular and Biomedical Sciences of the University of Bern.

AUTHOR CONTRIBUTIONS

Conceptualization, Y.F.-M. and T.K.; Investigation, D.B., E.L., Y.F.-M.; Writing-Original Draft, Y.F.-M., D.B., and T.K.; Writing-Review & Editing, Y.F.-M. and T.K.; Visualization, Y.F.-M. and D.B.; Formal Analysis, Y.F.-M.; Funding Acquisition, T.K.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: August 21, 2018

Revised: October 23, 2018

Accepted: November 1, 2018

Published: November 30, 2018

REFERENCES

- Alexander, K.A., Wang, X., Shibata, M., Clark, A.G., and Garcia-Garcia, M.J. (2015). TRIM28 controls genomic imprinting through distinct mechanisms during and after early genome-wide reprogramming. *Cell Rep.* *13*, 1194–1205.
- Bakheet, T., Hitti, E., Al-Saif, M., Moghrabi, W.N., and Khabar, K.S.A. (2018). The AU-rich element landscape across human transcriptome reveals a large proportion in introns and regulation by ELAVL1/HuR. *Biochim. Biophys. Acta* *1861*, 167–177.
- Baltz, A.G., Munschauer, M., Schwanhauser, B., Vasile, A., Murakawa, Y., Schueler, M., Youngs, N., Penfold-Brown, D., Drew, K., Milek, M., et al. (2012). The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. *Mol. Cell* *46*, 674–690.
- Beroukhi, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. (2010). The landscape of somatic copy-number alteration across human cancers. *Nature* *463*, 899–905.
- Biggar, K.K., and Storey, K.B. (2015). Insight into post-transcriptional gene regulation: stress-responsive microRNAs and their role in the environmental stress survival of tolerant animals. *J. Exp. Biol.* *218*, 1281–1289.
- Bunch, H., Zheng, X., Burkholder, A., Dillon, S.T., Motola, S., Birrane, G., Ebmeier, C.C., Levine, S., Fargo, D., Hu, G., et al. (2014). TRIM28 regulates RNA polymerase II promoter-proximal pausing and pause release. *Nat. Struct. Mol. Biol.* *21*, 876–883.
- Cano, F., Bye, H., Duncan, L.M., Buchet-Poyau, K., Billaud, M., Wills, M.R., and Lehner, P.J. (2012). The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation. *EMBO J.* *31*, 3596–3606.
- Carberry, S., D'Orsi, B., Monsefi, N., Salvucci, M., Bacon, O., Fay, J., Rehm, M., McNamara, D., Kay, E.W., and Prehn, J.M.H. (2018). The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer. *Cell Death Dis.* *9*, 125.
- Chen, L., Munoz-Antonia, T., and Cress, W.D. (2014). Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines. *PLoS One* *9*, e101040.
- Cheng, C.T., Kuo, C.Y., and Ann, D.K. (2014). KAP1 in charge of multiple missions: emerging roles of KAP1. *World J. Biol. Chem.* *5*, 308–320.
- Cui, Y., Yang, S., Fu, X., Feng, J., Xu, S., and Ying, G. (2014). High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer. *Int. J. Mol. Sci.* *16*, 363–377.

- Czerwinska, P., Shah, P.K., Tomczak, K., Klimczak, M., Mazurek, S., Sozanska, B., Biecek, P., Korski, K., Filas, V., Mackiewicz, A., et al. (2017). TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development. *Oncotarget* 8, 863–882.
- D’Orsi, B., Engel, T., Pfeiffer, S., Nandi, S., Kaufmann, T., Henshall, D.C., and Prehn, J.H. (2016). Bok is not pro-apoptotic but suppresses poly ADP-ribose polymerase-dependent cell death pathways and protects against excitotoxic and seizure-induced neuronal injury. *J. Neurosci.* 36, 4564–4578.
- Deng, B., Zhang, S., Zhang, Y., Miao, Y., Meng, X., and Guo, K. (2017). Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial-mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/ β -catenin signaling pathway. *Neoplasma* 64, 893–900.
- Diaz-Munoz, M.D., Bell, S.E., and Turner, M. (2015). Deletion of AU-rich elements within the Bcl2 3’UTR reduces protein expression and B cell survival in vivo. *PLoS One* 10, e0116899.
- Echeverry, N., Bachmann, D., Ke, F., Strasser, A., Simon, H.U., and Kaufmann, T. (2013). Intracellular localization of the BCL-2 family member BOK and functional implications. *Cell Death Differ.* 20, 785–799.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw, R., Jassal, B., Korninger, F., May, B., et al. (2018). The reactome pathway knowledgebase. *Nucleic Acids Res.* 46, D649–D655.
- Fallmann, J., Sedlyarov, V., Tanzer, A., Kovarik, P., and Hofacker, I.L. (2016). AREsite2: an enhanced database for the comprehensive investigation of AU/GU/U-rich elements. *Nucleic Acids Res.* 44, D90–D95.
- Fernandez-Marrero, Y., Bleicken, S., Das, K.K., Bachmann, D., Kaufmann, T., and Garcia-Saez, A.J. (2017). The membrane activity of BOK involves formation of large, stable toroidal pores and is promoted by cBID. *FEBS J.* 284, 711–724.
- Fitzgerald, S., Sheehan, K.M., O’Grady, A., Kenny, D., O’Kennedy, R., Kay, E.W., and Kijanka, G.S. (2013). Relationship between epithelial and stromal TRIM28 expression predicts survival in colorectal cancer patients. *J. Gastroenterol. Hepatol.* 28, 967–974.
- Friedman, J.R., Fredericks, W.J., Jensen, D.E., Speicher, D.W., Huang, X.P., Neilson, E.G., and Rauscher, F.J., 3rd (1996). KAP-1, a novel corepressor for the highly conserved KRAB repression domain. *Genes Dev.* 10, 2067–2078.
- Glisovic, T., Bachorik, J.L., Yong, J., and Dreyfuss, G. (2008). RNA-binding proteins and post-transcriptional gene regulation. *FEBS Lett.* 582, 1977–1986.
- Groner, A.C., Meylan, S., Ciuffi, A., Zangger, N., Ambrosini, G., Denervaud, N., Bucher, P., and Trono, D. (2010). KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. *PLoS Genet.* 6, e1000869.
- Hosoya, T., Clifford, M., Losson, R., Tanabe, O., and Engel, J.D. (2013). TRIM28 is essential for erythroblast differentiation in the mouse. *Blood* 122, 3798–3807.
- Hu, G., Kim, J., Xu, Q., Leng, Y., Orkin, S.H., and Elledge, S.J. (2009). A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. *Genes Dev.* 23, 837–848.
- Hu, M., Fu, X., Cui, Y., Xu, S., Xu, Y., Dong, Q., and Sun, L. (2015). Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance. *Int. J. Clin. Exp. Med.* 8, 17308–17320.
- Ishimaru, D., Zuraw, L., Ramalingam, S., Sengupta, T.K., Bandyopadhyay, S., Reuben, A., Fernandes, D.J., and Spicer, E.K. (2010). Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1). *J. Biol. Chem.* 285, 27182–27191.
- Iyengar, S., and Farnham, P.J. (2011). KAP1 protein: an enigmatic master regulator of the genome. *J. Biol. Chem.* 286, 26267–26276.
- Jin, X., Pan, Y., Wang, L., Zhang, L., Ravichandran, R., Potts, P.R., Jiang, J., Wu, H., and Huang, H. (2017). MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. *Oncogenesis* 6, e312.
- Kalkat, M., Garcia, J., Ebrahimi, J., Melland-Smith, M., Todros, T., Post, M., and Caniggia, I. (2013). Placental autophagy regulation by the BOK-MCL1 rheostat. *Autophagy* 9, 2140–2153.
- Ke, F.F.S., Vanyai, H.K., Cowan, A.D., Delbridge, A.R.D., Whitehead, L., Grabow, S., Czabotar, P.E., Voss, A.K., and Strasser, A. (2018). Embryogenesis and adult life in the absence of intrinsic apoptosis effectors BAX, BAK, and BOK. *Cell* 173, 1217–1230.e17.
- Leppek, K., Das, R., and Barna, M. (2018). Functional 5’ UTR mRNA structures in eukaryotic translation regulation and how to find them. *Nat. Rev. Mol. Cell Biol.* 19, 158–174.
- Li, F., Wang, Z., and Lu, G. (2018). TRIM28 promotes cervical cancer growth through the mTOR signaling pathway. *Oncol. Rep.* 39, 1860–1866.
- Li, J., Xi, Y., Li, W., McCarthy, R.L., Stratton, S.A., Zou, W., Li, W., Dent, S.Y., Jain, A.K., and Barton, M.C. (2017). TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation. *Oncogene* 36, 2991–3001.
- Liu, L., Zhao, E., Li, C., Huang, L., Xiao, L., Cheng, L., Huang, X., Song, Y., and Xu, D. (2013). TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. *Cancer Epidemiol.* 37, 71–78.
- Livi, C.M., Klus, P., Delli Ponti, R., and Tartaglia, G.G. (2016). catRAPID signature: identification of ribonucleoproteins and RNA-binding regions. *Bioinformatics* 32, 773–775.
- Llambi, F., Wang, Y.M., Victor, B., Yang, M., Schneider, D.M., Gingras, S., Parsons, M.J., Zheng, J.H., Brown, S.A., Pelletier, S., et al. (2016). BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. *Cell* 165, 421–433.
- Lunde, B.M., Moore, C., and Varani, G. (2007). RNA-binding proteins: modular design for efficient function. *Nat. Rev. Mol. Cell Biol.* 8, 479–490.
- Moosmann, P., Georgiev, O., Le Douarin, B., Bourquin, J.P., and Schaffner, W. (1996). Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. *Nucleic Acids Res.* 24, 4859–4867.
- Moravcikova, E., Krepela, E., Donnenberg, V.S., Donnenberg, A.D., Benkova, K., Rabachini, T., Fernandez-Marrero, Y., Bachmann, D., and Kaufmann, T. (2017). BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma. *Int. J. Cancer* 141, 2050–2061.
- Murata, T., Morita, N., Hikita, K., Kiuchi, K., Kiuchi, K., and Kaneda, N. (2005). Recruitment of mRNA-destabilizing protein TIS11 to stress granules is mediated by its zinc finger domain. *Exp. Cell Res.* 303, 287–299.
- Okamoto, K., Kitabayashi, I., and Taya, Y. (2006). KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. *Biochem. Biophys. Res. Commun.* 351, 216–222.
- Qi, Z.X., Cai, J.J., Chen, L.C., Yue, Q., Gong, Y., Yao, Y., and Mao, Y. (2016). TRIM28 as an independent prognostic marker plays critical roles in glioma progression. *J. Neurooncol.* 126, 19–26.
- Rabachini, T., Fernandez-Marrero, Y., Montani, M., Loforese, G., Sladky, V., He, Z., Bachmann, D., Wicki, S., Villunger, A., Stroka, D., et al. (2017). BOK promotes chemical-induced hepatocarcinogenesis in mice. *Cell Death Differ.* 25, 706–718.
- Schiavone, N., Rosini, P., Quattrone, A., Donnini, M., Lapucci, A., Citti, L., Bevilacqua, A., Nicolini, A., and Capaccioli, S. (2000). A conserved AU-rich element in the 3’ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. *FASEB J.* 14, 174–184.
- Schulman, J.J., Wright, F.A., Han, X., Zhuhan, E.J., Szczesniak, L.M., and Wojcikiewicz, R.J. (2016). The stability and expression level of Bok are governed by binding to inositol 1,4,5-trisphosphate receptors. *J. Biol. Chem.* 291, 11820–11828.
- Schulman, J.J., Wright, F.A., Kaufmann, T., and Wojcikiewicz, R.J. (2013). The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage. *J. Biol. Chem.* 288, 25340–25349.
- Sengupta, T.K., Bandyopadhyay, S., Fernandes, D.J., and Spicer, E.K. (2004). Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. *J. Biol. Chem.* 279, 10855–10863.
- Venkov, C.D., Link, A.J., Jennings, J.L., Plieth, D., Inoue, T., Nagai, K., Xu, C., Dimitrova, Y.N.,

Rauscher, F.J., and Neilson, E.G. (2007). A proximal activator of transcription in epithelial-mesenchymal transition. *J. Clin. Invest.* *117*, 482–491.

Vilborg, A., Glahder, J.A., Wilhelm, M.T., Bersani, C., Corcoran, M., Mahmoudi, S., Rosenstierne, M., Grander, D., Farnebo, M., Norrild, B., et al. (2009). The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. *Proc. Natl. Acad. Sci. U S A* *106*, 15756–15761.

Vlasova-St Louis, I., and Bohjanen, P.R. (2014). Post-transcriptional regulation of cytokine

signaling by AU-rich and GU-rich elements. *J. Interferon Cytokine Res.* *34*, 233–241.

Wei, C., Cheng, J., Zhou, B., Zhu, L., Khan, M.A., He, T., Zhou, S., He, J., Lu, X., Chen, H., et al. (2016). Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein. *Sci. Rep.* *6*, 29822.

Wigington, C.P., Jung, J., Rye, E.A., Belauret, S.L., Philpot, A.M., Feng, Y., Santangelo, P.J., and Corbett, A.H. (2015). Post-transcriptional regulation of programmed cell death 4 (PDCD4) mRNA by the RNA-binding proteins human

antigen R (HuR) and T-cell intracellular antigen 1 (TIA1). *J. Biol. Chem.* *290*, 3468–3487.

Zhao, W., Zhao, J., Hou, M., Wang, Y., Zhang, Y., Zhao, X., Zhang, C., and Guo, D. (2014). HuR and TIA1/TIAL1 are involved in regulation of alternative splicing of SIRT1 pre-mRNA. *Int. J. Mol. Sci.* *15*, 2946–2958.

Zheng, J.H., Grace, C.R., Guibao, C.D., McNamara, D.E., Llambi, F., Wang, Y.M., Chen, T., and Moldoveanu, T. (2018). Intrinsic instability of BOK enables membrane permeabilization in apoptosis. *Cell Rep.* *23*, 2083–2094.e6.

ISCI, Volume 9

Supplemental Information

**Negative Regulation of BOK Expression
by Recruitment of TRIM28 to Regulatory
Elements in Its 3' Untranslated Region**

Yuniel Fernandez-Marrero, Daniel Bachmann, Emanuel Lauber, and Thomas Kaufmann

SUPPLEMENTAL FIGURES

Figure S1 related to Figure 3. Occurrence of AU-, GU- and U-rich elements within the 3'UTR of selected BCL2 family members. The presence of regulatory elements within the 3'UTR of the indicated human genes were predicted using the publicly available tool AREsite2 (<http://rna.tbi.univie.ac.at/AREsite2>) and their absolute frequency plotted (left panel). The positions of the predicted motifs were color-coded according to the individual class and mapped on a normalized length version of each 3'UTR using the genomic coordinates as follows: $Motif\ position = \frac{|Motif_{start} - 3'UTR_{start}|}{|3'UTR_{start} - 3'UTR_{end}|}$ (right panel). Nucleotides are designated according to IUPAC convention; K=G or T, N= any base, W= A or T. Original data available online at the Mendeley Database; <http://dx.doi.org/10.17632/9dfn8m6sgd.1>.





Figure S2 related to Figure 5. Theoretical occurrence of RNA binding modules in the TRIM28 sequence. Amino acid sequence of human TRIM28 protein (Q13263) was used for the analysis for RNA binding propensity in the public web server http://s.tartaglialab.com/page/catrapid_group. Likelihood of binding above 0.5 indicates potential RNA-binding. The predicted modules are horizontally highlighted in pink on a superimposed cartoon depicting the functional domains of TRIM28. Original data available online at the Mendeley Database; <http://dx.doi.org/10.17632/9dfn8m6sgd.1>.



RBCC: Ring Finger B-Box Coiled-Coil Tripartite Motif
 HP1: HP1 Binding Box
 PHD: Plant Homeodomain type Zinc Finger
 BrD: Bromodomain

Figure S3 related to Figure 5. (A) SV40 WT MEF were transiently co-transfected with 2 μ g of plasmid mix (ratio 1:9; pcDNA3.EGFP/pcDNA3.humanTRIM28) and the endogenous BOK protein levels analyzed by immunoblotting after 48 hours. (B, C) Quantification of BOK abundance at both protein (B) and transcript (C) levels in the lung cancer cell lines NCI-H1299 and LFX-289 stably transduced with HA-tagged human TRIM28. *TRIM28* mRNA levels are much lower in the LFX-289 line, correlating with decreased mean fluorescence of IRES-EGFP. The data is presented as mean \pm SD, N=3. See Figure 5E for representative western blot.




Figure S4 related to Figure 6. Estimation of risk associated with *BOK* and *TRIM28* mRNA levels in several cancer types. Multiparametric Cox hazard ratio models using expression of *TRIM28* and *BOK* mRNA levels as continuous variables were prepared for thirty-three cancer types. 95% confidence interval and number of patients used in the analysis are included in the graph. Significant covariates are colour coded (red). See Table S2 for original data, <http://dx.doi.org/10.17632/9dfn8m6sgd.1#file-08fd9021-e239-4c81-906e-66bf80b92d1d>.






Figure S5 related to Figure 6. Overall survival of patients from different cancer types according to TRIM28 or BOK expression levels. Patients were classified into “high” or “low” strata according to the population median of *BOK* (upper panel) or *TRIM28* (lower panel) and the overall survival plotted as a function of each strata. Differences in survival were detected with the Log-Rank test. Significant differences were declared for p values below 0.05. See Table S2 for original data, <http://dx.doi.org/10.17632/9dfn8m6sgd.1#file-08fd9021-e239-4c81-906e-66bf80b92d1d>.



TRANSPARENT METHODS

Cell lines and cell culture

Dulbecco's Modified Eagle's Medium-high glucose (DMEM), RPMI 1640 Aqmedia™ and 100 mM cell culture grade sodium pyruvate were purchased from Sigma-Aldrich Chemie GmbH (Buchs, CH); penicillin/streptomycin (P/S) and trypsin-EDTA were purchased from Gibco (Thermo Fisher Scientific Switzerland, Reinach, CH). Ultra-low endotoxin fetal calf serum (FCS) was purchased from Pan Biotech (Aidenbach, DE). SV40 LT-immortalized mouse embryo fibroblasts (SV40 MEF) derived from *Bok*^{-/-} animals have been previously described (Echeverry et al., 2013). The human embryonal kidney cell line containing the temperature sensitive mutant of the SV-40 large T-antigen (HEK293T) was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, DE). The non-small cell lung cancer cell line LXF-289 and the large-cell lung carcinoma cell line NCI-H1299 were obtained from the European Collection of Authenticated Cell Culture (ECACC, Salisbury, UK) and the DSMZ respectively. The colon colorectal carcinoma cell line HCT-116 was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). *Bok*^{-/-} SV40 MEF and HEK293T cells were cultured in DMEM supplemented with 1 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin and 5 % FCS while cancer cell lines were cultured in RPMI 1640 supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 10 % FCS. All cells were kept in a humidified incubator at 37°C with 5 % CO₂. Human *BOK* cDNA harboring wildtype or URE mutated 3'UTR were cloned into pcDNA3.1 (see below), transfected into HEK293T cells and selected with 2.3 mg/mL G-418 (Gibco, Thermo Fisher Scientific Switzerland, Reinach, CH).

cDNA

Mouse *Bok* cDNA (ENSMUST00000027499.12, Cat#: MC206561, cloned into a pCMV6-Kan/Neo vector) was purchased from Origene (Rockville, MD, USA). Human *BOK* cDNA (ENST00000318407.4) was synthesized from isolated RNA derived from human immortalized hepatocytes (IHH cell line kindly provided by Prof. Thomas Brunner, University of Konstanz, DE). Briefly, 10⁷ cells were collected washed with saline and the RNA extracted using the SV Total RNA extraction kit followed by reverse transcription of 1 µg of total RNA using the M-MLV reverse transcriptase according to the manufacturer's instructions (Promega, Dübendorf, CH). Human *BOK* cDNA was then amplified with the primers forward 5'- GTAGAATTCCTCGCTGCCAGGCCCGACG-3' and reverse 5'- CATGCGCCGCTCTGTCTAAAT GACAACGA TCG-3' using the Phusion Hot Start Flex DNA Polymerase (New England Biolabs, Ipswich, MA, US), digested with *EcoRI*/*NotI* and cloned into the pcDNA3.1 vector.

PCR based subcloning and site directed mutagenesis

Mouse *Bok* constructs devoid of, or bearing combination of its 5' and/or 3'UTRs were amplified from the pCMV6-*Bok*(cDNA) plasmid and subcloned via the restriction sites *EcoRI/NotI* into the pcDNA3.1 vector using the following set of primers: *mmcDNA* forward 5'-TACGACTCACTATAGGGCG-3' reverse 5'-GTACGCGTAAGCTTGGGC-3'; *mmCDS* forward 5'-GTAGAATTCATGGAGGTGCTGCGGCGCTCTTCTG-3', reverse 5'-CTGGCGGCCGCTCATCTCT CTGGCAACAACAGGAAG-3'; *5'UTR-CDS* forward 5'-TACGACTCACTATAGGGCG-3', reverse 5'-CTGGCGGCCGCTCATCTCTCTGGCAACAACAGGAAG-3'; *mmCDS-3'UTR* forward 5'-GTAGAATTCATGGAGGTGCTGCGGCGCTCTTCTG-3', reverse 5'-GTACGCGTAAGCTTGGGC-3'. Truncated versions of the *Bok* 3'UTR were created by amplifying the whole pcDNA3/*mmBokCDS-3'UTR* construct except the desired area to delete using the following primers per construct: *mmCDS-3'UTR Δ 1* (deletion between positions 951-1134) forward 5'-CATTCTTTGTGGACCCTGG-3', reverse 5'-TCATCTCTCTGGCAACAACAGG-3'; *mmCDS-3'UTR Δ 2* (deletion between positions 1134-1341) forward 5'-GCTAATGCAGGAGAAGCCAG-3', reverse 5'-CAGACTCTGGCTTTCTCC-3'; *mmCDS-3'UTR Δ 3* (deletion between positions 1341-1575) forward 5'-GAAGAAGGTATCCCTAAGCC-3', reverse 5'-CAGAGTCCCCTTCAAGTCAA-3'. PCR-based mutagenesis of the ARE site (position 1049, AUUUUA \rightarrow GACGU) located in the mouse *Bok* 3'UTR was created using the pcDNA3/*mmBokCDS-3'UTR* as template and complementary primers carrying the desired sequence: forward 5'-AATTGGAGCGACGTGCCCTGGG-3', reverse 5'-TGAGTGAGGGAGGTGCTTTG-3'.

To create an expression construct of EGFP flanked by the 5'- and 3'-UTRs of *Bok*, or its ARE site mutated version, respectively, the EGFP ORF was amplified by PCR from the pEGFP-C3 (Clontech, USA) template using the primers forward 5'-ATGGTGAGCAAGGGCGAG-3' and reverse 5'-TCAGTTATCTAGATCCGGTGG-3' and cloned into pcDNA3/*mmBOK-cDNA* or pcDNA3/*mmBok-cDNA-3'UTRAREmut* in exchange for the *Bok* CDS (removed by PCR: forward primer 5'-GCTGGCCAACAGGGCAG-3', reverse primer 5'-GGCCGAAGCGCGGGCGA-3').

The human *BOK* coding sequence devoid of (hsCDS) or containing the 3'UTR (hsCDS-3'UTR) was amplified from the isolated cDNA (described above) using the following primers: hsCDS forward 5'-GTAGAATTCATGGAGGTGCTGCGGCGCTCTTCTG-3', reverse 5'-CATGCGGCCGCTCATCTCTCTGGCAGCAGCACGAAG-3'; hsCDS-3'UTR forward 5'-GTAGAATTCATGGAGGTGCTGCGGCGCTCTTCTG-3', reverse 5'-CATGCGGCCGCTCTGTCTAAAATGACAACGATCG-3' and subcloned using *EcoRI/NotI* into the pcDNA3.1 vector. Constructs with mutations in the predicted URE sites of the human *BOK* 3'UTR were created using pcDNA3.1/*hsBOK-CDS-3'UTR* as template and pairs of complementary primers as follows: *hsCDS-3'UTR URE mut1* (position 2224, AUUUUU \rightarrow GCAACG) forward 5'-CCCATCTGCTGCAACGGTGCTCATCC-3', reverse 5'-GTC ACCCTCACCTCCACTG-3'; *hsCDS-3'UTR URE mut2* (position 2635, AUUUUA \rightarrow GCAACG) forward 5'-GATCGTTGTGCAACGGACAGAGCGG-3', reverse 5'-GTTTGGAGAAGTTTATTA CCACCC-3', *hsCDS-3'UTR URE mut3* (position 2608, AAUAAA \rightarrow GCAUGC) forward 5'-GTAG GGGTGGTGCATGCCTTCTCCAAC-3', reverse 5'-CCTCCAGTGGGATCTCAATG-3'. Sequential mutagenesis PCRs were performed with the previous oligos to create double (*hsCDS-3'UTR UREmut1+2*) or triple (*hsCDS-3'UTR UREmut1-3*) URE mutants. Correct sequences of all generated constructs were confirmed by sequencing (Microsynth, Balgach, CH).

Transient transfection, quantitative real time RT-PCR analysis and immunoblotting

1 x 10⁶ HEK293T cells were seeded in 3 mL of media in a 6 well plate (Greiner Bio-One, Frickenhause, DE) and transfected with 2.5 µg of DNA using X-tremeGENE™ HP DNA Transfection Reagent (Roche, Rotkreuz, CH) according to the manufacturer's instructions. The transient transfection efficiency of BOK expression constructs was normalized by co-transfecting a second plasmid encoding an internal reporter, pEGFP or pcDNA3.1/FLAG-MCL-1, at a ratio of 1:10 of the target construct. Cells were harvested after 24 h and divided for RNA isolation and quantitative RT-PCR (qPCR) analysis or immunoblotting, respectively. RNA isolation, reverse transcription and PCR amplification were performed as described elsewhere (Echeverry et al., 2013). For qPCR analysis, *BOK* cDNA was amplified using the following specie specific primers: human forward 5'-CAGTCTGAGCCTGTGGTGAC-3', reverse 5'-TGATGCCTGCAGAGAAGATG-3'; mouse forward 5'-TTCTCAGCAGGTATCACATGG-3', reverse 5'-TAGCCAAGGTC TTGCGTACA-3'. Human β-actin was used as reference gene using the primers: forward 5'-CTGGCACCCAGCACAAATG-3', reverse: 5'-GGGCCGGACTCGTCATAC-3'. Mouse *Hprt* was used as reference gene in MEF: forward 5'-TGGATACAGGCCAGACTTTTGT 3', reverse 5'-CAGATTCAACTTGCGCTCATC-3'. For immunoblotting, unless otherwise indicated, all lysates were prepared in pre-heated H8 buffer (20 mM Tris-HCl pH 7.5, 2 mM EDTA, 2 mM EGTA, 1 % SDS, 100 mM DTT) during 5 min at 95°C followed by mechanical shearing with a 25G needle, centrifugation at 15'000 rpm and protein concentration estimation using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Reinach, CH). Equal amounts of lysates were prepared with reducing Laemmli buffer, separated on 12.5 % SDS-PAGE gels and blotted to Immobilon-FL membranes (0.45 µm pore PVDF, Merck Millipore, Schaffhausen CH). Membranes were probed with the following antibodies: rabbit monoclonal anti-BOK clone 1-5 (Echeverry et al., 2013), mouse anti-FLAG antibody (clone M5) and mouse anti-tubulin (clone B-5-1-2) from Sigma-Aldrich (Buchs, CH), rabbit anti-GFP (D5.1) from Cell Signaling Technology (Danvers, MA, US), rabbit anti-BAX (N-20: sc-493), mouse anti-TIF1β (D-7: sc-515790), mouse anti-SAFB2 (C-5: sc-514963), mouse anti-LSM5 (G-5: sc-398656) and mouse anti-TIAR (TIAL-1) (G-6: sc-398372) from Santa Cruz Biotechnologies (Dallas, TX, USA), rabbit anti-BAK (BAK-NT) from Merck Millipore (Schaffhausen, CH) and rat anti-HA (clone 3F10) from Roche (Rotkreuz, CH). Commercial secondary antibodies specific for mouse, rabbit or rat IgG coupled to the infrared fluorophores IRDye®680CW or IRDye®800CW were purchased from LI-COR Biosciences (Bad Homburg, DE). Immunoblot signals were acquired in an Odyssey Fc (LI-COR Biosciences) and quantified using the Image Studio Lite Software version 5.25 (LI-COR Biosciences).

BOK 3'UTR RNA probe synthesis and pulldown of URE-binding proteins

Biotinylated RNA probes encoding the human *BOK* CDS-3'UTR and its URE triple mutant counterpart (UREmut1-3) were synthesized using the commercial AmpliScribe T7-Flash Biotin-RNA Transcription kit (Lucigen, WI, USA) following the manufacturer's instructions. Cytosolic or nuclear lysates were prepared using a manual Dounce homogenizer from 3x10⁷ HEK293T cells which were harvested, washed with saline and resuspended in hypotonic buffer (10 mM Tris-HCl pH 7.4, 10 mM KCl, 2 mM MgCl₂, 1 mM DTT, complete

protease inhibitor cocktail (Roche, Rotkreuz, CH) or nuclear isolation buffer (25 mM Tris-HCl pH 7.4, 150 mM KCl, 2 mM MgCl₂, 1 mM DTT, 0.5 % NP-40, complete protease inhibitor cocktail), respectively. Three independent pulldowns of proteins binding to the probes was performed as described elsewhere (Bai et al., 2016). Briefly, the RNA biotinylated probes were folded by sequential thermal stress (2 min at 95 °C, 2 min at 4 °C, 30 min at 25 °C) in 2x RNA structure buffer (20 mM Tris-HCl pH 7.4, 0.2 M KCl, 20 mM MgCl₂, 2 mM DTT, 0.8 IU of recombinant RNasin ribonuclease inhibitor (Promega, Dübendorf, CH). 10 µg of each probe was incubated with a total of 250 µg of cytosolic and nuclear lysates mix (1:1 w/w) in the presence of RNase inhibitor during 30 min at room temperature, then supplemented with 2.5 mg/mL of heparin (Sigma-Aldrich) and further incubated for 10 min at room temperature, mixed with 50 µL of 50 % slurry of Streptavidin-Sepharose High Performance beads (GE Healthcare, Glattbrugg, CH) and incubated overnight at 4°C on a rotating wheel. The beads were then washed three times with hypotonic buffer and 10 % of each sample was used to confirm the presence of proteins by SDS-PAGE and silver staining and the rest was air-dried and send for shotgun mass spectrometry analysis.

Mass spectrometry

Proteins bound to the streptavidin beads were directly digested on the beads with 100 ng sequencing grade trypsin (Promega, Dübendorf, CH) for 6 h at 37°C after the following treatment: the dry beads were suspended in 30 µL of 8 M urea in 50 mM Tris-HCl, pH 8.0, followed by reduction of the proteins with 3 µL 0.1 M DTT for 30 min at 37 °C and alkylation by addition of 3 µL 0.5 M iodoacetamide for 30 min at 37 °C in the dark. The urea concentration was then diluted to 2 M by addition of 20 mM Tris-HCl pH 8.0 containing 2 mM CaCl₂. Digestion was stopped by adding 1/20 volume of 20 % (v/v) trifluoroacetic acid. An aliquot of 5 µL of each digest was analysed three times by LC-MS/MS on an EASY-nLC1000 chromatograph connected to a QExactive mass spectrometer (Thermo Fisher Scientific, Reinach, CH). Peptides were trapped on a Precolumn (C18 PepMap100, 5 µm, 100 Å, 300 µm × 5 mm, Thermo Fisher Scientific, Reinach, CH) and separated in backflush mode on a C18 column (3 µm, 100 Å, 75µm x 15 cm, Nikkyo Technos, Tokyo, Japan) by applying a 40-minutes gradient of 5-40 % acetonitrile in water, 0.1 % formic acid, at a flow rate of 300 nL/min. The Full Scan method was set to a resolution of 70'000 with an automatic gain control (AGC) target of 1x10⁶ and maximum ion injection time of 50 ms. The data-dependent method for ten precursor ion fragmentations per cycle was applied with the following settings: resolution 17'500, AGC of 1x10⁵, maximum ion time of 110 milliseconds, mass window 2 m/z, collision energy 27, under fill ratio 1 %, charge exclusion of unassigned and 1⁺ ions, and peptide match preferred, respectively.

LC-MS/MS data was processed with MaxQuant (version 1.5.4.1) using default settings for peak detection, trypsin cleavage disregarding the proline rule, allowing up to three missed cleavages, variable oxidation on methionine, acetylation of protein N-termini, and strict carbamidomethylation of cysteines, using the SwissProt human protein sequence database released in April 2016, respectively. Match between runs was used within each sample group with a retention time window of 0.7 min. Protein identifications were

accepted only if at least two razor peptides at a 1 % false discovery rate (FDR) cut-off were identified.

Mass spectrometry data processing and visualization

For label-free protein quantification, we relied on the MaxQuant built-in label-free quantification (LFQ) algorithm (Cox et al., 2014) and applied a top3 peptide approach (Braga-Lagache et al., 2016). For the latter, all peptide identifications in the evidence output file from MaxQuant were median normalized before imputation of missing values from the normal distribution of \log_2 -transformed peptides using a down shift of 1.8 and a width of 0.3 standard deviations (default settings in Perseus software, version 1.5.5.3) (Tyanova et al., 2016). Missing values imputation was carried out, when there was at least one peptide identification in the nine replicates from the same sample set, otherwise the intensity was set to zero according to recommendations by Lazar and colleagues (Lazar et al., 2016). The three most intense peptide intensities were then summed to the protein group intensity. The LFQ values were also \log_2 -transformed, and missing values imputed as described above if there was at least one LFQ in a sample group, otherwise a zero was set. Fake protein group intensities were imputed (down shift of 2.5 and a width of 0.3 standard deviations) in each sample group where no protein intensity was available before performing Student's two-sample t tests. Statistical significance of differentially pulled down proteins was assigned with a 1 % permutation-based FDR adjustment and if there was at least a two-fold abundance change between sample groups.

The proteins detected on each sample were explored and visualized using a Venn diagram (Bardou et al., 2014) and the package *ggplot2* (Wickham, 2009) within the R environment (R Core Team, 2017).

Functional enrichment analysis

Genes having an expression ratio wild-type-to-UREmut probe greater than 1.5 were used to perform a gene ontology statistical overrepresentation tests using the Panther Tool (<http://pantherdb.org/>, version 13.1 Released 2018-02-03) (Mi et al., 2017). The results of the analysis were restricted to GO terms contained into the Molecular Function, Biological Process, Cellular Component and Reactome Pathways categories with terms showing significant enrichment scores (Fisher's exact test with false discovery rate corrected for multiple comparison, adjusted p-value ≤ 0.05) using the human genome as background.

RNA interference experiments and TRIM28 overexpression

The selected candidates TIAL1, TRIM28, SAFB2 and LSM5 were validated using *in vitro* transcribed endoribonuclease-prepared short interfering RNA pools, with a luciferase specific control RLUC (MISSION esiRNA, Sigma-Aldrich). 2×10^5 HEK293T cells stably expressing either human BOK CDS-3'UTR or CDS-3'UTR(URE mut1-3), respectively, were seeded in a 24 well plate, allowed to attach for 7 h and transfected with 0.5 μg of the desired esiRNA using the X-tremeGENE siRNA Transfection Reagent (Roche,

Rotkreuz, CH) following the provider's instructions. Cells were harvested after 72 h and target gene expression was evaluated by western blot.

The pKH3-TRIM28 was a gift from Fanxiu Zhu (Addgene plasmid # 45569) (Liang et al., 2011) and was used for transient expression of a C-terminally HA-tagged TRIM28 in the target cells HCT-116, NCI-H1299, HEK293T and MEF. For stable expression, *TRIM28* CDS was extracted by PCR using the oligonucleotides 5'-GACCGAATTCATGTACC CATACGATGTTC-3' and 5'-GATTGAATTCTCAGGGGCCATCAC-3' and subcloned using *EcoRI* into the lentiviral CAD-G-Whiz vector (Rizzi et al., 2007). The sequence and correct orientation of the expression cassette was confirmed by sequencing. The resulting plasmid was co-transfected with the pMD2GVSV-G envelope and psPAX2 packaging plasmids into HEK293T cells using X-tremeGENE™ HP DNA Transfection Reagent (Roche, Rotkreuz, CH) in order to produce lentiviral particles. Particles were harvested from the supernatant, filtered through a 0.22 µm disc filter (Merck Millipore, Schaffhausen CH), mixed with polybrene at a final concentration of 8 µg/mL and used directly to transduce target cell lines. Transduction efficiency was checked by the presence of the IRES-translated EGFP reporter included in the CAD-G-Whiz plasmid.

Patient datasets

Clinical and gene expression data of 9639 samples from 33 cancer types included in the cohort TCGA-TARGET-GTEX (Vivian et al., 2017) were retrieved through the UCSC Xena browser (<http://xena.ucsc.edu>). The clinical data matrix contains 41 descriptors (<https://xenabrowser.net/datapages/?cohort=TCGA%20TARGET%20GTEX>, version 17.10.2017) while the gene expression corresponds to the transformed normalized transcript count (RNAseq, ILLUMINA platform, $\log_2(\text{norm_count}+1)$, version 12.04.2016). Cox proportional-hazard models were recreated in R software using the package *survival* (Therneau, 2015) by modelling the overall survival as a function of the expression levels of *BOK* and *TRIM28* (used as continuous variables). The patients from the selected cancer types were classified into "high" and "low" strata according to the median expression of *BOK* and *TRIM28* genes. Spearman's correlation between *BOK* and *TRIM28* was calculated on the strata and Kaplan-Meier curves were prepared using the package *survminer* (Kassambara and Kosinski, 2018). Differences in overall survival was determined using a Log-rank test, declaring significant differences for p-values ≤ 0.05 .

Statistical analysis

Unless otherwise indicated, the data from at least three independent experiments is presented as mean \pm SD using the Prism Software v6 (GraphPad, La Jolla, CA, US). Potential differences between treatments were detected using a one-way ANOVA followed by a Tukey's *post-hoc* test. Significant values were represented according to the following convention: $p \geq 0.05^{\text{ns}}$, $p \leq 0.05^*$, $p \leq 0.01^{**}$, $p \leq 0.001^{***}$ and $p \leq 0.0001^{****}$.

SUPPLEMENTAL TABLES

Table S1 related to Figure 4. Results from shotgun mass spectrometry analysis using mRNA biotinylated probes. Details the identified proteins, peptide numbers, principal component analysis, clustered analysis, t-test and FDR correction for each independent replicate pulled down with the BOK-3'UTR wild type or URE-mutated RNA probes. Available online at the Mendeley Database;
<http://dx.doi.org/10.17632/9dfn8m6sgd.1#file-5706e58e-b2c5-4eea-925e-09073d7ff8d5>.

Table S2 related to Figure 6. Clinical and expression matrix used for Cox regression, survival and correlation analysis. Dataset containing *TRIM28* and *BOK* gene expression matched to clinical parameters in 33 cancer types by patient ID following the TCGA nomenclature. Include detailed description of the original data source as well as the manipulations performed in this work to stratified patients according to the selected gene expression. Available online at the Mendeley Database;
<http://dx.doi.org/10.17632/9dfn8m6sgd.1#file-08fd9021-e239-4c81-906e-66bf80b92d1d>.

SUPPLEMENTAL REFERENCES

Bai, Q., Bai, Z., and Sun, L. (2016). Detection of RNA-binding Proteins by In Vitro RNA Pull-down in Adipocyte Culture. *J Vis Exp*.

Bardou, P., Mariette, J., Escudie, F., Djemiel, C., and Klopp, C. (2014). jvenn: an interactive Venn diagram viewer. *BMC Bioinformatics* *15*, 293.

Braga-Lagache, S., Buchs, N., Iacovache, M.I., Zuber, B., Jackson, C.B., and Heller, M. (2016). Robust Label-free, Quantitative Profiling of Circulating Plasma Microparticle (MP) Associated Proteins. *Mol Cell Proteomics* *15*, 3640-3652.

Cox, J., Hein, M.Y., Lubner, C.A., Paron, I., Nagaraj, N., and Mann, M. (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics* *13*, 2513-2526.

Echeverry, N., Bachmann, D., Ke, F., Strasser, A., Simon, H.U., and Kaufmann, T. (2013). Intracellular localization of the BCL-2 family member BOK and functional implications. *Cell Death Differ* *20*, 785-799.

Kassambara, A., and Kosinski, M. (2018). survminer: Drawing Survival Curves using 'ggplot2'.

Lazar, C., Gatto, L., Ferro, M., Bruley, C., and Burger, T. (2016). Accounting for the Multiple Natures of Missing Values in Label-Free Quantitative Proteomics Data Sets to Compare Imputation Strategies. *J Proteome Res* *15*, 1116-1125.

Liang, Q., Deng, H., Li, X., Wu, X., Tang, Q., Chang, T.H., Peng, H., Rauscher, F.J., 3rd, Ozato, K., and Zhu, F. (2011). Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. *J Immunol* *187*, 4754-4763.

Mi, H., Huang, X., Muruganujan, A., Tang, H., Mills, C., Kang, D., and Thomas, P.D. (2017). PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res* *45*, D183-D189.

R Core Team (2017). R: A Language and Environment for Statistical Computing. (Vienna, Austria, R Foundation for Statistical Computing).

Rizzi, M., Tschan, M.P., Britschgi, C., Britschgi, A., Hugli, B., Grob, T.J., Leupin, N., Mueller, B.U., Simon, H.U., Ziemiecki, A., *et al.* (2007). The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells. *J Leukoc Biol* *81*, 1599-1608.

Therneau, T.M. (2015). A Package for Survival Analysis in S.

Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann, M., and Cox, J. (2016). The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat Methods* *13*, 731-740.

Vivian, J., Rao, A.A., Nothaft, F.A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A.D., Musselman-Brown, A., *et al.* (2017). Toil enables reproducible, open source, big biomedical data analyses. *Nat Biotechnol* *35*, 314-316.

Wickham, H. (2009). *ggplot2* : elegant graphics for data analysis (New York: Springer).